
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the Desmopressin Acetate Injection USP".
Filed with NSE · · 3 pages · English

Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the Desmopressin Acetate Injection USP".
Caplin Point Laboratories Limited on 6ix
Follow Caplin Point Laboratories into a list and get an email when it puts out news.
Follow Caplin Point Laboratories